印度农村三价灭活流感疫苗3年集群随机对照试验的效力
在印度三个村庄开展集群随机双盲对照试验,将家庭随机分配至三价灭活流感疫苗(IIV3)或灭活脊灰疫苗(IPV)组,每年接种一次共3年。
要点
- 两组不良事件发生率相似,最常见为发热和注射部位压痛。
核心结论
- IIV3对儿童流感感染提供可变直接保护,间接保护在直接保护最高的年份显著。
研究设计与样本
- 在印度三个村庄开展集群随机、盲法、对照研究,集群定义为共享庭院的住户,儿童年龄6个月至10岁符合接种条件。
- 3208户入组,其中1959户有符合接种条件的儿童,1010户分配至IIV3组、949户分配至IPV组,每年接种一次共3年。
- 主要效力结局为接种儿童发热急性呼吸道疾病中实验室确诊流感,改良意向治疗分析;间接效果次要结局为未接种家庭接触者的发热急性呼吸道疾病。
关键数值与推荐
- IIV3组儿童不良事件:第1年1632名中225名(12%)、第2年1718名中375名(22%)、第3年1673名中209名(12%)。
- IPV组儿童不良事件:第1年1730名中216名(13%)、第2年1825名中380名(21%)、第3年1796名中235名(13%)。
- 两组最常见反应为发热和注射部位压痛,无疫苗相关死亡。
临床怎么用
- 在资源有限地区,儿童接种IIV3可降低自身流感感染,直接保护随年度变化。
- 评估疫苗接种规划效果时,应结合直接保护水平考虑间接保护。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Paediatric vaccination against influenza can result in indirect protection, by reducing transmission to their unvaccinated contacts. We investigated whether influenza vaccination of children would protect them and their household members in a resource-limited setting. METHODS: We did a cluster-randomised, blinded, controlled study in three villages in India. Clusters were defined as households (ie, dwellings that shared a courtyard), and children aged 6 months to 10 years were eligible for vaccination as and when they became age-eligible throughout the study. Households were randomly assigned (1:1) by a computer-based system to intramuscular trivalent inactivated influenza vaccine (IIV3) or a control of inactivated poliovirus vaccine (IPV) in the beginning of the study; vaccination occurred once a year for 3 years. The primary efficacy outcome was laboratory-confirmed influenza in a vaccinated child with febrile acute respiratory illness, analysed in the modified intention-to-treat population (ie, children who received at least one dose of vaccine, were under surveillance, and had not an influenza infection within 15 days of last vaccine dose). The secondary outcome for indirect effectiveness (surveillance study) was febrile acute respiratory illness in an unvaccinated household member of a vaccine study participant. Data from each year (year 1: November, 2009, to October, 2010; year 2: October, 2010, to October, 2011; and year 3: October, 2011, to May, 2012) were analysed separately. Safety was analysed among all participants who were vaccinated with at least one dose of the vaccine. This trial is registered with ClinicalTrials.gov, number NCT00934245. FINDINGS: Between Nov 1, 2009, to May 1, 2012, we enrolled 3208 households, of which 1959 had vaccine-eligible children. 1010 households were assigned to IIV3 and 949 households were assigned to IPV. In 3 years, we vaccinated 4345 children (2132 with IIV3 and 2213 with IPV) from 1868 households (968 with IIV3 and 900 with IPV) with 10 813 unvaccinated household contacts. In year 1, influenza virus was detected in 151 (10%) of 1572 IIV3 recipients and 206 (13%) of 1633 of IPV recipients (total IIV3 vaccine efficacy 25·6% [95% CI 6·8-40·6]; p=0·010). In year 2, 105 (6%) of 1705 IIV3 recipients and 182 (10%) of 1814 IPV recipients had influenza (vaccine efficacy 41·0% [24·1-54·1]; p<0·0001). In year 3, 20 (1%) of 1670 IIV3 recipients and 81 (5%) of 1786 IPV recipients had influenza (vaccine efficacy 74·2% [57·8-84·3]; p<0·0001). In year 1, total vaccine efficacy against influenza A(H1N1)pdm09 was 14·5% (-20·4 to 39·3). In year 2, total vaccine efficacy against influenza A(H3N2) was 64·5% (48·5-75·5). Total vaccine efficacy against influenza B was 32·5% (11·3-48·6) in year 1, 4·9% (-38·9 to 34·9) in year 2, and 76·5% (59·4-86·4) in year 3. Indirect vaccine effectiveness was statistically significant only in year 3 (38·1% [7·4-58·6], p=0·0197) when influenza was detected in 39 (1%) of 4323 IIV3-allocated and 60 (1%) of 4121 IPV-allocated household unvaccinated individuals. In the IIV3 group, 225 (12%) of 1632 children in year 1, 375 (22%) of 1718 in year 2, and 209 (12%) of 1673 in year 3 had an adverse reaction (compared with 216 [13%] of 1730, 380 [21%] of 1825, and 235 [13%] of 1796, respectively, in the IPV group). The most common reactions in both groups were fever and tenderness at site. No vaccine-related deaths occurred in either group. INTERPRETATION: IIV3 provided variable direct and indirect protection against influenza infection. Indirect protection was significant during the year of highest direct protection and should be considered when quantifying the effect of vaccination programmes. FUNDING: US Centers for Disease Control and Prevention.
引用
- Sullender WM, Fowler KB, Gupta V, et al. Efficacy of inactivated trivalent influenza vaccine in rural India: a 3-year cluster-randomised controlled trial. Lancet Glob Health. 2019. PMID: 31200893. doi:10.1016/S2214-109X(19)30079-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。